...
首页> 外文期刊>Current opinion in solid state & materials science >Polymeric micelles for cancer therapy: 3 C's to enhance efficacy
【24h】

Polymeric micelles for cancer therapy: 3 C's to enhance efficacy

机译:用于癌症治疗的聚合物胶束:3 C提高功效

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

During the past few years, polymeric micelles (PM), which can accommodate various different hydrophobic anticancer agents within their core, have received substantial attention as EPR-targeted drug delivery systems for cancer therapy. PM can be modified to confer several attractive properties, such as stimuli-responsiveness and active targeting. However, PM still face challenges of instability in systemic circulation and premature drug leakage, often leading to improper in vivo efficacy. These shortcomings have triggered research toward the development of next-generation PM. Here, we propose a 3C approach for making PM more effective, encompassing (core-) crosslinking, covalent drug entrapment and integration therapies based on intrinsically active targeting ligands, and we show that the integration of these three concepts within one PM formulation leads to nanomedicines with substantially improved in vivo efficacy.
机译:在过去的几年中,高分子胶束(PM)可以在其核心中容纳各种不同的疏水性抗癌剂,作为针对EPR的癌症治疗药物递送系统受到了广泛关注。可以对PM进行修饰,使其具有多种吸引人的特性,例如刺激反应性和主动靶向性。但是,PM仍然面临全身循环不稳定和药物过早泄漏的挑战,这通常会导致体内功效不当。这些缺点引发了对下一代PM开发的研究。在这里,我们提出了一种3C方法来使PM更加有效,包括基于固有活性的靶向配体的(核心)交联,共价药物截留和整合疗法,并且我们证明了将这三个概念整合到一个PM制剂中可产生纳米药物。具有显着改善的体内功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号